YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024.
Second Quarter 2024 Highlights:
U.S. GAAP Results (U.S. dollars in thousands, except for per share data) | ||
Q2 2024 | Q2 2023 | |
Revenues | $86,449 | $136,081 |
Gross Margins | 80 % | 84 % |
Net Income | $23,818 | $55,729 |
Earnings per Diluted Share | $0.28 | $0.65 |
*Non-GAAP Results (U.S. dollars in thousands, except for per share data) | ||
Q2 2024 | Q2 2023 | |
Gross Margins | 81 % | 84 % |
Net Income | $28,976 | $62,234 |
Earnings per Diluted Share | $0.34 | $0.72 |
**Pro-Forma Non-GAAP Results (U.S. dollars in thousands, except for per share data) | ||
Q2 2024 | Q2 2023 | |
Revenue | $102,622 | $136,081 |
Gross Margins | 82 % | 84 % |
Net Income | $39,764 | $62,234 |
Earnings per Diluted Share | $0.46 | $0.72 |
*Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A | ||
** Pro-forma non-GAAP results includes pre-orders of new platforms not yet delivered and excludes share-based compensation. |
Management Comments
"The second quarter was challenging for InMode and for the aesthetics industry in general," said Moshe Mizrahy, Chief Executive Officer. "The quarter was impacted mainly by macroeconomic factors and longer production time of new and complex platforms. However, we are encouraged by the level of interest and orders of our new platforms, Ignite and Optimus Max, and we believe that these advanced platforms will be growth catalysts.
"In addition, as the leading company in the industry, we continue to invest in research and development, and our innovation pipeline is strong. As we offer unique platforms and technologies that require adjustments to the production lines, I would like to recognize the commitment and dedication of our employees who work tirelessly to expedite the production and fulfill orders during these times," Mizrahy concluded.
Second Quarter 2024 Financial Results
Total GAAP revenues for the second quarter of 2024 reached $86.4 million, a decrease of 36.5% compared to $136.1 million in second quarter of 2023. Pro-forma revenue reached $102.6 million.
"During the second quarter, we began delivering the new platforms and we are on track to complete all deliveries within the next several months," said Yair Malca, Chief Financial Officer. "Additionally, we are pleased to report that by the end of July 2024 we have successfully completed our third share repurchase program, acquiring 8.37 million shares for the amount of $150 million."
GAAP gross margin for the second quarter of 2024 was 80% compared to a gross margin of 84% for the Second quarter of 2023. *Non-GAAP gross margin for the second quarter of 2024 was 81% compared to a gross margin of 84% for the second quarter of 2023.
**Pro-forma non-GAAP gross margin for the second quarter of 2024 was 82%.
GAAP operating margin for the second quarter of 2024 was 21%, compared to an operating margin of 42% in the Second quarter of 2023. *Non-GAAP operating margin for the second quarter of 2024 was 27% compared to 47% for the Second quarter of 2023. **Pro-forma non-GAAP operating margin for the second quarter of 2024 was 34%. This decrease was primarily attributable to the decrease in systems sales in North America.
InMode reported GAAP net income of $23.8 million, or $0.28 per diluted share, in the second quarter of 2024, compared to $55.7 million, or $0.65 per diluted share, in the second quarter of 2023. On a *non-GAAP basis, InMode reported net income of $29.0 million, or $0.34 per diluted share, in the second quarter of 2024, compared to $62.2 million, or $0.72 per diluted share, in the second quarter of 2023. **Pro-forma non-GAAP net income of $39.8 million, or $0.46 per diluted share, in the second quarter of 2024.
2024 Financial Outlook
Management provided an outlook for the full year of 2024 ending December 31, 2024. Based on our current estimates, management expects:
This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. See "Forward- | |
*Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A | |
** Pro-forma non-GAAP results includes pre-orders of new platforms not yet delivered and excludes share-based compensation. | |
Based on our 2024 Financial Outlook, it is not expected that there should be any difference between our Pro-forma non-GAAP results and |
The Current Situation in Israel
Regarding the current situation in Israel, management would like to assure investors that the Company is prioritizing the safety and well-being of its employees, and all its team are safe. However, an inability to promptly receive needed supplies and materials due to the ongoing and unpredictable nature of the conflict in Israel and the surrounding region may adversely impact our ability to commercialize and manufacture our product candidates and products in a timely manner. This could cause several delays and/or issues for our operations, which in turn would have a material adverse impact on our ability to commercialize our product candidates and our financial condition.
Use of Non-GAAP Financial Measures
In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, non-GAAP operating margin as well as Pro-forma Non-GAAP revenue, pro-forma Non-GAAP net income, pro-forma non-GAAP earnings per diluted share and pro-forma non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.
Conference Call Information
Mr. Moshe Mizrahy, Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer, Mr. Shakil Lakhani, President of North America, will host a conference call today, August 1, 2024, at 8:30 a.m. Eastern Time to discuss the second 2024 financial results.
The Company encourages participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10190152/fcd9be3160.
Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.
For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.
U.S. Toll-Free Dial-in Number: 1-833-316-0562
Israel Toll- Free Dial-in Number: 1-80-921-2373
International Dial-in Number: 1-412-317-5736
Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=GpRhmBhV
At:
8:30 a.m. Eastern Time
5:30 a.m. Pacific Time
The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from August 1, 2024, at 12 p.m. Eastern Time to August 15, 2024, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers:
Replay Dial-in U.S TOLL-FREE: 1-877-344-7529
Replay Dial-in Canada TOLL-FREE: 855-669-9658
Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 2791553
To access the replay using an international dial-in number, please select the link below:
https://services.choruscall.com/ccforms/replay.html
A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
Forward-Looking Statements
The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2024 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 13, 2024, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.
Company Contact: Yair Malca Chief Financial Officer Phone: (949) 305-0108 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Relations Contact: Miri Segal MS-IR LLC Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
INMODE LTD. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (U.S. dollars in thousands, except for per share data) (Unaudited) | |||||
Three months ended | Six months ended | ||||
2024 | 2023 | 2024 | 2023 | ||
REVENUES | 86,449 | 136,081 | 166,733 | 242,155 | |
COST OF REVENUES | 17,116 | 22,054 | 33,481 | 40,308 | |
GROSS PROFIT | 69,333 | 114,027 | 133,252 | 201,847 | |
OPERATING EXPENSES: | |||||
Research and development | 3,698 | 3,567 | 7,216 | 6,669 | |
Sales and marketing | 45,055 | 51,059 | 84,850 | 92,772 | |
General and administrative | 2,266 | 2,392 | 4,780 | 4,400 | |
TOTAL OPERATING EXPENSES | 51,019 | 57,018 | 96,846 | 103,841 | |
OPERATIONS INCOME | 18,314 | 57,009 | 36,406 | 98,006 | |
Finance income, net | 8,690 | 4,445 | 16,674 | 7,734 | |
INCOME BEFORE INCOME TAXES | 27,004 | 61,454 | 53,080 | 105,740 | |
INCOME TAXES | 3,186 | 5,725 | 5,566 | 9,506 | |
NET INCOME | 23,818 | 55,729 | 47,514 | 96,234 | |
EARNINGS PER SHARE: | |||||
Basic | 0.28 | 0.67 | 0.56 | 1.16 | |
Diluted | 0.28 | 0.65 | 0.55 | 1.12 | |
WEIGHTED AVERAGE NUMBER OF SHARES | |||||
Basic | 83,878 | 83,405 | 84,205 | 83,280 | |
Diluted | 85,890 | 85,650 | 86,520 | 85,579 |
INMODE LTD. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except for per share data) (Unaudited) | ||
June 30, 2024 | December 31, 2023 | |
Assets | ||
CURRENT ASSETS: | ||
Cash and cash equivalents | 91,997 | 144,411 |
Marketable securities | 333,517 | 373,647 |
Short-term bank deposits | 303,694 | 223,547 |
Accounts receivable, net of allowance for credit losses | 38,154 | 42,362 |
Prepaid expense and other receivables | 23,003 | 16,268 |
Inventories | 52,627 | 45,095 |
TOTAL CURRENT ASSETS | 842,992 | 845,330 |
NON-CURRENT ASSETS: | ||
Accounts receivable, net of allowance for credit losses | 3,100 | 3,670 |
Deferred income tax asset | 1,402 | 1,506 |
Operating lease right-of-use assets | 9,246 | 9,698 |
Property and equipment, net | 2,396 | 2,382 |
Other investments | 700 | 700 |
TOTAL NON-CURRENT ASSETS | 16,844 | 17,956 |
TOTAL ASSETS | 859,836 | 863,286 |
Liabilities and shareholders' equity | ||
CURRENT LIABILITIES: | ||
Accounts payable | 15,548 | 13,966 |
Contract liabilities | 43,610 | 10,923 |
Other liabilities | 38,532 | 39,247 |
TOTAL CURRENT LIABILITIES | 97,690 | 64,136 |
NON-CURRENT LIABILITIES: | ||
Contract liabilities | 3,455 | 3,766 |
Other liabilities | 1,899 | 1,399 |
Operating lease liabilities | 5,671 | 6,613 |
TOTAL NON-CURRENT LIABILITIES | 11,025 | 11,778 |
TOTAL LIABILITIES | 108,715 | 75,914 |
TOTAL SHAREHOLDERS' EQUITY | 751,121 | 787,372 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 859,836 | 863,286 |
INMODE LTD. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in thousands, except for per share data) (Unaudited) | ||||||
Three months ended | Six months ended | |||||
2024 | 2023 | 2024 | 2023 | |||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net income | 23,818 | 55,729 | 47,514 | 96,234 | ||
Adjustments required to reconcile net income to net cash provided by operating activities: | ||||||
Depreciation and amortization | 177 | 184 | 342 | 372 | ||
Share-based compensation expenses | 5,158 | 6,505 | 9,141 | 10,714 | ||
Change in allowance for credit losses of trade receivable | 97 | 261 | 284 | 239 | ||
Loss on marketable securities, net | 112 | - | 141 | - | ||
Finance income, net | (5,040) | (1,197) | (9,797) | (2,709) | ||
Deferred income taxes | (56) | 43 | (93) | 62 | ||
Changes in operating assets and liabilities: | ||||||
Decrease (increase) in accounts receivable | (4,814) | (7,949) | 4,494 | (5,708) | ||
Increase in other receivables | (4,048) | (3,791) | (6,717) | (4,020) | ||
Decrease (increase) in inventories | (1,025) | 2,243 | (7,532) | 1,329 | ||
Increase (decrease) in accounts payable | 2,325 | 1,308 | 1,582 | (2,947) | ||
Increase (decrease) in other liabilities | 2,241 | 7,211 | (5,562) | (15,832) | ||
Increase (decrease) in contract liabilities (current and non-current) | 23,114 | (7,547) | 32,376 | (3,621) | ||
Net cash provided by operating activities | 42,059 | 53,000 | 66,173 | 74,113 | ||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Investment in short-term deposits | (55,000) | (25,000) | (86,297) | (28,000) | ||
Proceeds from short-term deposits | 13,500 | 31,500 | 13,500 | 34,500 | ||
Purchase of fixed assets | (246) | (194) | (358) | (535) | ||
Purchase of marketable securities | (64,129) | (54,190) | (185,693) | (132,119) | ||
Proceeds from sale of marketable securities | 33,910 | - | 47,375 | - | ||
Proceeds from maturity of marketable securities | 89,690 | 60,891 | 181,808 | 111,605 | ||
Net cash provided by (used in) investing activities | 17,725 | 13,007 | (29,665) | (14,549) | ||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Repurchase of ordinary shares | (88,980) | - | (88,980) | - | ||
Exercise of options | 395 | 827 | 629 | 2,500 | ||
Net cash provided by (used in) financing activities | (88,585) | 827 | (88,351) | 2,500 | ||
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH | (132) | 60 | (571) | 251 | ||
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (28,933) | 66,894 | (52,414) | 62,315 | ||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 120,930 | 92,961 | 144,411 | 97,540 | ||
CASH AND CASH EQUIVALENTS AT END OF PERIOD | 91,997 | 159,855 | 91,997 | 159,855 |
Revision of prior period financial information
The Company revised certain items within the investing activities with no impact on the net cash used in investing activities. The items impacted were "Investment in short-term deposits" and "Proceeds from short-term deposits" which were decreased by $75,000 and $78,000 for the three months and six months ended June 30,2023 respectively and "Purchase of marketable securities" and "Proceeds from maturity of marketable securities" which were decreased by $0, and $40,423 for the three months and six months ended June 30, 2023.
These changes have no impact on our previously reported consolidated total cash flows from operating activities, financing activities and investing activities in the periods stated above as well as net income and net change in cash and cash equivalents.
The Company evaluated the materiality of the adjustments, individually and in the aggregate, considering both qualitative and quantitative factors, and concluded that it was immaterial to the Company's prior periods' consolidated financial information. Since the revision was not material to any prior interim period or annual consolidated financial statements, no amendments to previously filed interim or annual periodic financial information was required. Consequently, the Company has revised the historical consolidated financial information presented herein for the impact of the above.
INMODE LTD. CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS (U.S. dollars in thousands, except for per share data) (Unaudited) | |||||||||||
Three months ended June 30, | Six months ended June 30, | ||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||
Revenues by Category: | |||||||||||
Capital Equipment revenues - United States | 34,799 | 41 % | 73,828 | 54 % | 65,658 | 39 % | 123,579 | 51 % | |||
Capital Equipment revenues - International | 30,606 | 35 % | 40,635 | 30 % | 57,529 | 35 % | 77,008 | 32 % | |||
Total Capital Equipment revenues | 65,405 | 76 % | 114,463 | 84 % | 123,187 | 74 % | 200,587 | 83 % | |||
Consumables and service revenues | 21,044 | 24 % | 21,618 | 16 % | 43,546 | 26 % | 41,568 | 17 % | |||
Total Revenue | 86,449 | 100 % | 136,081 | 100 % | 166,733 | 100 % | 242,155 | 100 % | |||
Three months ended June 30, | Six months ended June 30, | |||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||
% | % | % | % | |||||||||
United States | International | Total | United States | International | Total | United States | International | Total | United States | International | Total | |
Revenues by Technology: | ||||||||||||
Minimal-Invasive | 85 | 86 | 87 | 86 | 73 | 81 | 87 | 84 | 86 | 88 | 74 | 83 |
Hands-Free | 11 | 4 | 7 | 11 | 6 | 9 | 9 | 3 | 6 | 10 | 6 | 8 |
Non-Invasive | 4 | 10 | 6 | 3 | 21 | 10 | 4 | 13 | 8 | 2 | 20 | 9 |
100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
INMODE LTD. RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME (U.S. dollars in thousands, except for per share data) (Unaudited) | |||||||
Three months ended June 30, 2024 |
Three months ended June 30, 2023 | ||||||
GAAP |
Share Based |
Non-GAAP |
GAAP |
Share Based |
Non-GAAP | ||
REVENUES | 86,449 | - | 86,449 | 136,081 | - | 136,081 | |
COST OF REVENUES | 17,116 | (471) | 16,645 | 22,054 | (547) | 21,507 | |
GROSS PROFIT | 69,333 | 471 | 69,804 | 114,027 | 547 | 114,574 | |
OPERATING EXPENSES: | |||||||
Research and development | 3,698 | (559) | 3,139 | 3,567 | (757) | 2,810 | |
Sales and marketing | 45,055 | (3,824) | 41,231 | 51,059 | (4,731) | 46,328 | |
General and administrative | 2,266 | (304) | 1,962 | 2,392 | (470) | 1,922 | |
TOTAL OPERATING |
51,019 |
(4,687) |
46,332 |
57,018 |
(5,958) | 51,060 | |
OPERATIONS INCOME | 18,314 | 5,158 | 23,472 | 57,009 | 6,505 | 63,514 | |
Finance income (expense), net |
8,690 |
- |
8,690 |
4,445 |
- | 4,445 | |
INCOME BEFORE INCOME TAXES | 27,004 | 5,158 | 32,162 | 61,454 | 6,505 | 67,959 | |
INCOME TAXES | 3,186 | - | 3,186 | 5,725 | - | 5,725 | |
NET INCOME | 23,818 | 5,158 | 28,976 | 55,729 | 6,505 | 62,234 | |
EARNINGS PER SHARE: | |||||||
Basic |
0.28 |
0.35 |
0.67 | 0.75 | |||
Diluted | 0.28 | 0.34 | 0.65 | 0.72 | |||
WEIGHTED AVERAGE NUMBER OF | |||||||
Basic | 83,878 | 83,878 | 83,405 | 83,405 | |||
Diluted | 85,890 | 85,900 | 85,650 | 86,243 |
Six months ended June 30, 2024 | Six months ended June 30, 2023 | |||||
GAAP | Share Based | Non-GAAP | GAAP | Share Based | Non-GAAP | |
REVENUES | 166,733 | - | 166,733 | 242,155 | - | 242,155 |
COST OF REVENUES | 33,481 | (880) | 32,601 | 40,308 | (901) | 39,407 |
GROSS PROFIT | 133,252 | 880 | 134,132 | 201,847 | 901 | 202,748 |
OPERATING EXPENSES: | ||||||
Research and development | 7,216 | (987) | 6,229 | 6,669 | (1,258) | 5,411 |
Sales and marketing | 84,850 | (6,707) | 78,143 | 92,772 | (7,769) | 85,003 |
General and administrative | 4,780 | (567) | 4,213 | 4,400 | (786) | 3,614 |
TOTAL OPERATING EXPENSES | 96,846 | (8,261) | 88,585 | 103,841 | (9,813) |
94,028 |
OPERATIONS INCOME | 36,406 | 9,141 | 45,547 | 98,006 | 10,714 |
108,720 |
Finance income (expense),net | 16,674 | - | 16,674 | 7,734 | - | 7,734 |
INCOME BEFORE INCOME TAXES | 53,080 | 9,141 | 62,221 | 105,740 | 10,714 | 116,454 |
INCOME TAXES | 5,566 | - | 5,566 | 9,506 | - | 9,506 |
NET INCOME | 47,514 | 9,141 | 56,655 | 96,234 | 10,714 | 106,948 |
EARNINGS PER SHARE: | ||||||
Basic | 0.56 | 0.67 | 1.16 | 1.28 | ||
Diluted | 0.55 | 0.65 | 1.12 | 1.24 | ||
WEIGHTED AVERAGE NUMBER OF | ||||||
Basic | 84,205 | 84,205 | 83,280 | 83,280 | ||
Diluted | 86,520 | 86,531 | 85,579 | 86,062 |
Last Trade: | US$17.19 |
Daily Change: | 0.04 0.23 |
Daily Volume: | 859,892 |
Market Cap: | US$1.310B |
September 04, 2024 August 06, 2024 July 31, 2024 July 17, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB